Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients : Correlations with DMTs and clinical variables
Copyright © 2023. Published by Elsevier Inc..
Disease-modifying therapies (DMTs) can affect vaccine responses in individuals with multiple sclerosis (MS). We assessed the humoral and T-cell responses following SARS-CoV-2 mRNA vaccination in MS patients receiving various DMTs. We prospectively enrolled 243 participants, including 113 healthy control subjects and 130 MS patients. Blood samples for detecting SARS-CoV-2 antibodies were collected at three time points: T0, before the first vaccine dose; T1, before the second dose; and T2, one month after the second dose. In a subgroup of 51 patients and 20 controls, samples were collected at T0 and T2 to assess the T-cell immune response to the Spike antigen of SARS-CoV-2 using ELISPOT-IFNγ. The IgG levels in patients treated with fingolimod and ocrelizumab (159.1 AU/ml and 467.1 AU/ml, respectively) were significantly lower than those in healthy controls and patients on other DMTs (P < 0.0001). The mean Ig titers were higher in patients with an absolute lymphocyte count ≥1000 cells/mm3 compared to those with a count between 500 and 1000 and with a count <500 (mean ± SD:7205.6 ± 7339.2, 2413.1 ± 4515.4 and 165.9 ± 152.2, respectively; p = 0.008). We found correlations between antibody levels and age (r = 0.233, p = 0.008). A positive Spike-specific T-cell response was detectable in 100 % of vaccinated healthy controls and patients treated with teriflunomide, dimethyl-fumarate, and natalizumab, in 90.5 % of fingolimod patients, and in 63.8 % of ocrelizumab patients. There is a correlation between IgG-specific titer after SARS-CoV-2 vaccination and clinical variables (age, lymphocyte count). Notably, a T-cell-specific response to SARS-CoV-2 developed in patients treated with fingolimod and ocrelizumab, even with lower rates of humoral response.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics - 21(2024), 2 vom: 19. März, Seite e00307 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barone, Stefania [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 Vaccines |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 28.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neurot.2023.e00307 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367278758 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367278758 | ||
| 003 | DE-627 | ||
| 005 | 20240329000410.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neurot.2023.e00307 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1353.xml |
| 035 | |a (DE-627)NLM367278758 | ||
| 035 | |a (NLM)38237381 | ||
| 035 | |a (PII)S1878-7479(23)01943-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barone, Stefania |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients |b Correlations with DMTs and clinical variables |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 28.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a Disease-modifying therapies (DMTs) can affect vaccine responses in individuals with multiple sclerosis (MS). We assessed the humoral and T-cell responses following SARS-CoV-2 mRNA vaccination in MS patients receiving various DMTs. We prospectively enrolled 243 participants, including 113 healthy control subjects and 130 MS patients. Blood samples for detecting SARS-CoV-2 antibodies were collected at three time points: T0, before the first vaccine dose; T1, before the second dose; and T2, one month after the second dose. In a subgroup of 51 patients and 20 controls, samples were collected at T0 and T2 to assess the T-cell immune response to the Spike antigen of SARS-CoV-2 using ELISPOT-IFNγ. The IgG levels in patients treated with fingolimod and ocrelizumab (159.1 AU/ml and 467.1 AU/ml, respectively) were significantly lower than those in healthy controls and patients on other DMTs (P < 0.0001). The mean Ig titers were higher in patients with an absolute lymphocyte count ≥1000 cells/mm3 compared to those with a count between 500 and 1000 and with a count <500 (mean ± SD:7205.6 ± 7339.2, 2413.1 ± 4515.4 and 165.9 ± 152.2, respectively; p = 0.008). We found correlations between antibody levels and age (r = 0.233, p = 0.008). A positive Spike-specific T-cell response was detectable in 100 % of vaccinated healthy controls and patients treated with teriflunomide, dimethyl-fumarate, and natalizumab, in 90.5 % of fingolimod patients, and in 63.8 % of ocrelizumab patients. There is a correlation between IgG-specific titer after SARS-CoV-2 vaccination and clinical variables (age, lymphocyte count). Notably, a T-cell-specific response to SARS-CoV-2 developed in patients treated with fingolimod and ocrelizumab, even with lower rates of humoral response | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 mRNA vaccine | |
| 650 | 4 | |a Humoral response | |
| 650 | 4 | |a Multiple sclerosis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a T-cell response | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a Fingolimod Hydrochloride |2 NLM | |
| 650 | 7 | |a G926EC510T |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Palmieri, Camillo |e verfasserin |4 aut | |
| 700 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Rania, Vincenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Pascarella, Angelo |e verfasserin |4 aut | |
| 700 | 1 | |a Abatino, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Bruno, Pietro Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Casarella, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquale, Marilisa |e verfasserin |4 aut | |
| 700 | 1 | |a Manzo, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a De Sarro, Giovambattista |e verfasserin |4 aut | |
| 700 | 1 | |a Gambardella, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Valentino, Paola |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics |d 2007 |g 21(2024), 2 vom: 19. März, Seite e00307 |w (DE-627)NLM167471872 |x 1878-7479 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2024 |g number:2 |g day:19 |g month:03 |g pages:e00307 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neurot.2023.e00307 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2024 |e 2 |b 19 |c 03 |h e00307 | ||